Penumbra is hoping that its early successes will foreshadow greater breakthroughs. The global interventional therapies firm designs, develops, makes and markets innovative medical devices for two major markets, neuro and peripheral vascular. The company's products address ischemic stroke and hemorrhagic stroke (blockage or rupture of blood vessels in the brain), and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures (the removal or treatment of blockages or ruptures of blood vessels). The company's products provide specialist physicians with a means to drive improved clinical outcomes through faster and safer procedures. Penumbra went public in 2015.